Prognostic factors of survival and rapid progression in782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie
Tóm tắt
Từ khóa
Tài liệu tham khảo
Yagoda, 1995, Chemotherapy for advanced renal-cell carcinoma: 1983–1993, Semin Oncol, 22, 42
Rini, 2000, Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer, J Clin Oncol, 18, 2419, 10.1200/JCO.2000.18.12.2419
Bukowski, 1997, Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2, Cancer, 80, 1198, 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H
Childs, 2000, Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation, N Engl J Med, 343, 750, 10.1056/NEJM200009143431101
Medical Research Council Renal Cancer Collaborators, 1999, Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial, Lancet, 353, 14, 10.1016/S0140-6736(98)03544-2
Pyrhonen, 1999, Prospective randomized trial of interferon α-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer, J Clin Oncol, 17, 2859, 10.1200/JCO.1999.17.9.2859
Elson, 1988, Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma, Cancer Res, 48, 7310
De Forges, 1988, Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis, Semin Surg Oncol, 4, 149, 10.1002/ssu.2980040302
Palmer, 1992, Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2, Ann Oncol, 3, 475, 10.1093/oxfordjournals.annonc.a058239
Fossa, 1994, Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-α, Eur J Cancer, 30, 1310, 10.1016/0959-8049(94)90179-1
Lopez Hänninen, 1996, Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients, J Urol, 155, 19, 10.1016/S0022-5347(01)66527-3
Motzer, 1999, Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma, J Clin Oncol, 17, 2530, 10.1200/JCO.1999.17.8.2530
Négrier, 1998, Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma, N Engl J Med, 338, 1272, 10.1056/NEJM199804303381805
Ravaud, 1998, Subcutaneous interleukin-2, interferon α-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Francais d’Immunotherapie, J Clin Oncol, 16, 2728, 10.1200/JCO.1998.16.8.2728
Négrier, 2000, Treatment of patients with metastatic renal cell carcinoma with a combination of subcutaneous interleukin-2 and interferon α with or without fluorouracil, J Clin Oncol, 18, 4009, 10.1200/JCO.2000.18.24.4009
Négrier, 1999, Combination of cytokines in metastatic renal cell carcinoma (MRCC). Is the subcutaneous (sc) route less active than the intravenous (iv) route?, Proc Am Soc Clin Oncol, 331a, 18
Ljungberg, 1997, Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma, Eur J Cancer, 33, 1794, 10.1016/S0959-8049(97)00179-2
Blay, 1992, Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma, Cancer Res, 52, 3317
Kaplan, 1958, Non-parametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452
Mantel, 1966, Evaluation of survival data and two new rank order statistics arising in its consideration, Cancer Chemother Rep, 50, 163
Motzer, 2000, Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma, J Clin Oncol, 18, 1928, 10.1200/JCO.2000.18.9.1928
Gold, 1997, Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2, Cancer J Sci Am, 3, S85